Nanotechnology Stocks To Watch Now – March 23rd

OSI Systems, Virpax Pharmaceuticals, NVE, Biodexa Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares in companies that research, develop, or manufacture products using nanoscale materials and processes. These companies often innovate in fields such as electronics, medicine, energy, and materials science, leveraging the unique properties of materials measured on the nanoscale to potentially transform existing technologies. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ OSIS traded down $3.65 during trading hours on Friday, reaching $193.78. 337,321 shares of the stock traded hands, compared to its average volume of 170,605. The stock has a 50 day simple moving average of $192.85 and a two-hundred day simple moving average of $169.01. OSI Systems has a 1 year low of $126.57 and a 1 year high of $220.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25. The company has a market cap of $3.26 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 1.81 and a beta of 1.20.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Virpax Pharmaceuticals stock traded down $0.43 during mid-day trading on Friday, hitting $2.07. The company’s stock had a trading volume of 2,207,175 shares, compared to its average volume of 175,917. The business has a 50 day moving average price of $0.29 and a 200-day moving average price of $0.47. Virpax Pharmaceuticals has a 12 month low of $1.85 and a 12 month high of $106.75.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded up $0.59 during mid-day trading on Friday, hitting $65.99. The company’s stock had a trading volume of 47,414 shares, compared to its average volume of 20,731. The stock has a market cap of $319.19 million, a price-to-earnings ratio of 21.29 and a beta of 1.08. The business has a 50 day moving average price of $71.42 and a 200-day moving average price of $76.12. NVE has a 12 month low of $63.65 and a 12 month high of $90.24.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

BDRX traded down $0.23 during trading on Friday, hitting $1.77. 324,878 shares of the stock traded hands, compared to its average volume of 513,743. The company has a 50-day moving average price of $3.67. Biodexa Pharmaceuticals has a 12-month low of $1.71 and a 12-month high of $74.00.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNN traded down $0.13 during trading hours on Friday, reaching $4.14. 30,198 shares of the company traded hands, compared to its average volume of 76,842. Clene has a 12 month low of $3.82 and a 12 month high of $9.20. The company’s fifty day moving average price is $4.57 and its two-hundred day moving average price is $4.94. The company has a market capitalization of $34.47 million, a price-to-earnings ratio of -0.78 and a beta of 0.27.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNNW stock remained flat at $0.03 during midday trading on Friday. Clene has a 52 week low of $0.02 and a 52 week high of $0.08. The company’s fifty day moving average price is $0.04 and its 200-day moving average price is $0.04.